Vertaling van "clearest clinical risk factor involved " (Nederlands → Frans) :

This project was set up following the observation that the clearest clinical risk factor involved in suicide is a previous attempted suicide.
La mise en place de ce projet part du constat que le facteur de risque clinique le plus clair concernant le suicide est la tentative de suicide.

How frequent is suicidal behaviour in the general population? What tendencies can be observed over time with respect to sociodemographic factors and clinical risk factors?
Quelle est l’occurrence du comportement suicidaire dans la population générale, quelles sont les tendances à travers le temps, au niveau des facteurs sociodémographiques et des facteurs de risques cliniques?

With attempted suicides the clearest and most significant predictive risk factor for fatal suicidal behaviour, particular attention should be paid to providing adequate care and follow-up.
La tentative de suicide étant le facteur de risque du comportement suicidaire fatal le plus clair et le plus significatif en termes de prédiction, une attention toute particulière doit être portée à sa prise en charge et au suivi de celle-ci.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Its clinical manifestations are looked upon as the final result of a negative spiral that sets in if the risk factors can no longer be counterbalanced by the protective factors that each individual possesses to a certain extent.
Ce qui se présente de façon clinique est considéré comme le résultat final d’une spirale négative qui s’installe si les facteurs de risque ne peuvent plus être contrebalancés par les facteurs de protection dont chacun dispose dans une certaine mesure.

Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

At the level of those involved the risk factors that need to be taken into consideration are those regarding the research sites themselves.
At the level of those involved the risk factors that need to be taken into consideration are those regarding the research sites themselves.

There is a risk that dealing with access to means might only affect the external causes involved in committing the act, without taking into account the other factors.
Des actions au niveau de l’accessibilité aux moyens risquent de n’agir que sur les causes externes de passage à l’acte sans prendre en compte les autres facteurs.